VENT Study highlights endobronchial approaches to emphysema treatment

Pulmonx, an emerging leader in interventional pulmonology, announced today that the New England Journal of Medicine has published the results of the largest prospective, randomized, controlled study completed to date of endobronchial approaches to emphysema treatment, the VENT Study (Endobronchial Valve for Emphysema PalliatioN Trial). The published results of the VENT Study highlight the potential of the Pulmonx Zephyr® Endobronchial Valve (EBV) to improve the lives of patients suffering with certain types of emphysema. In the days leading up to the publication, several physician investigators also presented results of the European arm of the study, known as EURO-VENT, at the annual meeting of the European Respiratory Society (ERS) in Barcelona, Spain. The EURO-VENT data confirmed most of the positive results of the U.S. VENT Study and offered new analyses that highlight significant clinical benefits linked to target lung lobe volume reduction.

“Although we defined 'high responders' as patients with ≥55% target lobe volume reduction, it is likely that patients may benefit from smaller reductions in target lobe volume.”